GlassScriptPhysician profile
Elisa Giusto
NPI 1174015259
$2,460.24
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,594 · 2020: $392 · 2021: $353 · 2022: $121.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $494.35 | 2019-2021 | |
| Novo Nordisk INC | $262.98 | 2019 | |
| Sunovion Pharmaceuticals INC. | $240.78 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $227.94 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $199.60 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $124.80 | 2019 | |
| Amgen INC. | $124.80 | 2021 | |
| Novartis Pharmaceuticals Corporation | $124.80 | 2019 | |
| Esperion Therapeutics, INC. | $123.00 | 2020 | |
| Sanofi-Aventis U.S. LLC | $101.99 | 2019 | |
| Gilead Sciences, INC. | $99.60 | 2020 | |
| Vertiflex, INC. | $99.51 | 2019 | |
| Lilly USA, LLC | $92.68 | 2022 | |
| Janssen Pharmaceuticals, INC | $69.89 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $44.96 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $28.56 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elisa Giusto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.